TY - JOUR
T1 - Increased protein-conjugated acrolein and amyloid-β40/42 ratio in plasma of patients with mild cognitive impairment and Alzheimer's disease
AU - Waragai, Masaaki
AU - Yoshida, Madoka
AU - Mizoi, Mutsumi
AU - Saiki, Ryotaro
AU - Kashiwagi, Keiko
AU - Takagi, Kiyoshi
AU - Arai, Hiroyuki
AU - Tashiro, Jun
AU - Hashimoto, Makoto
AU - Iwai, Naomichi
AU - Uemura, Kenichi
AU - Igarashi, Kazuei
PY - 2012
Y1 - 2012
N2 - The objective of this study was to determine whether plasma levels of acrolein, a compound that causes cell damage, and amyloid-β (Aβ) are useful biochemical markers for Alzheimer's disease (AD). The study included 221 elderly subjects divided into 101 non-demented [33 healthy control and 68 non-demented subjects with white matter hyperintensity (nd-WMH)], 50 mild cognitive impairment (MCI), and 70 AD. Increases in both protein-conjugated acrolein (PC-Acro) and Aβ40/42 ratio were observed in MCI and AD patients compared with values in control subjects. When the combined measurements of PC-Acro and Aβ40/42 ratio were evaluated using the median value of the relative risk value for dementia, they were in the order AD (0.98) ≥ MCI (0.97) > nd-WMH (0.83) > control (0.35). The results indicate that measurements of PC-Acro and Aβ40/42 ratio not only detect MCI and AD patients but also nd-WMH subjects. Furthermore, both PC-Acro and Aβ40/42 ratio in plasma for 120 MCI and AD patients were significantly higher than those for 101 control and nd-WMH subjects, indicating that both values become useful biochemical markers for MCI and AD subjects.
AB - The objective of this study was to determine whether plasma levels of acrolein, a compound that causes cell damage, and amyloid-β (Aβ) are useful biochemical markers for Alzheimer's disease (AD). The study included 221 elderly subjects divided into 101 non-demented [33 healthy control and 68 non-demented subjects with white matter hyperintensity (nd-WMH)], 50 mild cognitive impairment (MCI), and 70 AD. Increases in both protein-conjugated acrolein (PC-Acro) and Aβ40/42 ratio were observed in MCI and AD patients compared with values in control subjects. When the combined measurements of PC-Acro and Aβ40/42 ratio were evaluated using the median value of the relative risk value for dementia, they were in the order AD (0.98) ≥ MCI (0.97) > nd-WMH (0.83) > control (0.35). The results indicate that measurements of PC-Acro and Aβ40/42 ratio not only detect MCI and AD patients but also nd-WMH subjects. Furthermore, both PC-Acro and Aβ40/42 ratio in plasma for 120 MCI and AD patients were significantly higher than those for 101 control and nd-WMH subjects, indicating that both values become useful biochemical markers for MCI and AD subjects.
KW - Alzheimer's disease
KW - amyloid-β
KW - magnetic resonance imaging
KW - plasma biomarker
KW - protein-conjugated acrolein
KW - white matter hyperintensity
UR - http://www.scopus.com/inward/record.url?scp=84867617173&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867617173&partnerID=8YFLogxK
U2 - 10.3233/JAD-2012-120253
DO - 10.3233/JAD-2012-120253
M3 - Article
C2 - 22751175
AN - SCOPUS:84867617173
VL - 32
SP - 33
EP - 41
JO - Journal of Alzheimer's Disease
JF - Journal of Alzheimer's Disease
SN - 1387-2877
IS - 1
ER -
